Entering the Therapeutics Age: A New Era for HHT Treatment (Recorded)
Lately, there’s been an exciting wave of news about HHT therapies. Several clinical trials are now underway, biotech companies are investing heavily in HHT research, and new treatments are closer than ever to becoming reality. We’re entering this new “therapeutics era” for HHT, and Dr. Hanny Al-Samkari, Director of the Massachusetts General Hospital HHT CoE, outlines what this transformation means for patients and families. This discussion includes groundbreaking advancements like pomalidomide, pazopanib, Diagonal’s Agonist Antibody, and Vaderis’ VAD044. These treatments represent new hope for managing and treating HHT symptoms more effectively.
